Literature DB >> 10508007

Molecular basis of rifampin resistance in Streptococcus pneumoniae.

T Padayachee1, K P Klugman.   

Abstract

Rifampin resistance among South African clinical isolates of Streptococcus pneumoniae was shown to be due to missense mutations within the rpoB gene. Sequence analysis of 24 rifampin-resistant isolates revealed the presence of mutations within cluster I as well as novel mutations in an area designated pneumococcus cluster III. Of the 24 isolates characterized, only 1 resistant isolate did not contain any mutations in the regions sequenced. Either the cluster I or the cluster III mutations separately conferred MICs of 32 to 128 microg/ml. Clinical isolate 55, for which the MIC was 256 microg/ml, was noted to contain 9 of the 10 mutations identified, which included the cluster I and cluster III mutations. As in Escherichia coli, it is possible that cluster I (amino acids 406 to 434) and cluster III (amino acids 523 to 600) of S. pneumoniae interact to form part of the antibiotic binding site, thus accounting for the very high MIC observed for isolate 55. PCR products containing cluster I or cluster III mutations were able to transform rifampin-susceptible S. pneumoniae to resistance. Although many of the isolates studied displayed identical sequences, pulsed-field gel electrophoresis analysis revealed that the isolates were not of clonal origin.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10508007      PMCID: PMC89483          DOI: 10.1128/AAC.43.10.2361

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Reconstitution of bacterial DNA-dependent RNA-polymerase from isolated subunits as a tool for the elucidation of the role of the subunits in transcription.

Authors:  A Heil; W Zillig
Journal:  FEBS Lett       Date:  1970-12       Impact factor: 4.124

2.  REGULATION OF THE TRANSFORMABILITY OF PHEUMOCOCCAL CULTURES BY MACROMOLECULAR CELL PRODUCTS.

Authors:  A TOMASZ; R D HOTCHKISS
Journal:  Proc Natl Acad Sci U S A       Date:  1964-03       Impact factor: 11.205

3.  Molecular evolution of rifampicin resistance in Streptococcus pneumoniae.

Authors:  M Enright; P Zawadski; P Pickerill; C G Dowson
Journal:  Microb Drug Resist       Date:  1998       Impact factor: 3.431

4.  The use of rifampin in the treatment of nontuberculous infections: an overview.

Authors:  M A Sande
Journal:  Rev Infect Dis       Date:  1983 Jul-Aug

5.  Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis.

Authors:  A Telenti; P Imboden; F Marchesi; D Lowrie; S Cole; M J Colston; L Matter; K Schopfer; T Bodmer
Journal:  Lancet       Date:  1993-03-13       Impact factor: 79.321

6.  Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase beta subunit in rifampin-resistant Mycobacterium tuberculosis strains from New York City and Texas.

Authors:  V Kapur; L L Li; S Iordanescu; M R Hamrick; A Wanger; B N Kreiswirth; J M Musser
Journal:  J Clin Microbiol       Date:  1994-04       Impact factor: 5.948

7.  Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance.

Authors:  D J Jin; C A Gross
Journal:  J Mol Biol       Date:  1988-07-05       Impact factor: 5.469

8.  Mu-induced rifamycin-resistant mutations not located in the rpoB gene of Escherichia coli.

Authors:  M C Kollenda; D Kamp; G R Hartmann
Journal:  Mol Gen Genet       Date:  1986-07

9.  Direct, automated detection of rifampin-resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymorphism analysis.

Authors:  A Telenti; P Imboden; F Marchesi; T Schmidheini; T Bodmer
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Characterization of rifampin-resistance in pathogenic mycobacteria.

Authors:  D L Williams; C Waguespack; K Eisenach; J T Crawford; F Portaels; M Salfinger; C M Nolan; C Abe; V Sticht-Groh; T P Gillis
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

View more
  14 in total

1.  Impact of Antimicrobial Resistance on the Treatment of Invasive Pneumococcal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-10       Impact factor: 3.725

2.  rpoB mutations in Streptococcus mitis clinical isolates resistant to rifampin.

Authors:  Wafa Achour; Olfa Guenni; Marguerite Fines; Roland Leclercq; Assia Ben Hassen
Journal:  Antimicrob Agents Chemother       Date:  2004-07       Impact factor: 5.191

3.  New species genetic approach to identify strains of mitis group streptococci that are donors of rifampin resistance to Streptococcus pneumoniae.

Authors:  María-José Ferrándiz; Carmen Ardanuy; Josefina Liñares; Luz Balsalobre; María Teresa García; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-11-01       Impact factor: 5.191

4.  Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes.

Authors:  Steve Mullin; David M Rothstein; Christopher K Murphy
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

5.  Compensatory evolution in rifampin-resistant Escherichia coli.

Authors:  M G Reynolds
Journal:  Genetics       Date:  2000-12       Impact factor: 4.562

6.  rpoB sequence analysis of cultured Tropheryma whippelii.

Authors:  M Drancourt; A Carlioz; D Raoult
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

7.  PCR-based ordered genomic libraries: a new approach to drug target identification for Streptococcus pneumoniae.

Authors:  Aimee E Belanger; Angel Lai; Marcia A Brackman; Donald J LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

8.  Frequency, spectrum, and nonzero fitness costs of resistance to myxopyronin in Staphylococcus aureus.

Authors:  Aashish Srivastava; David Degen; Yon W Ebright; Richard H Ebright
Journal:  Antimicrob Agents Chemother       Date:  2012-09-24       Impact factor: 5.191

9.  In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus.

Authors:  Christopher K Murphy; Steve Mullin; Marcia S Osburne; John van Duzer; Jim Siedlecki; Xiang Yu; Kathy Kerstein; Michael Cynamon; David M Rothstein
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Detection of nucleotide variability in rpoB in both rifampin-sensitive and rifampin-resistant strains of Chlamydia trachomatis.

Authors:  Ute Dreses-Werringloer; Ingrid Padubrin; Lars Köhler; Alan P Hudson
Journal:  Antimicrob Agents Chemother       Date:  2003-07       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.